ICI-VPH: Impact of dosing schedules with Human papillomavirus vaccine [Impact Des Calendriers d'Immunisation Contre Les HPV]

Trial Profile

ICI-VPH: Impact of dosing schedules with Human papillomavirus vaccine [Impact Des Calendriers d'Immunisation Contre Les HPV]

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 03 Jun 2017

At a glance

  • Drugs Human papillomavirus vaccine recombinant quadrivalent Merck (Primary)
  • Indications Human papillomavirus infections
  • Focus Therapeutic Use
  • Most Recent Events

    • 02 Mar 2017 Status changed from recruiting to active, no longer recruiting.
    • 04 Feb 2015 Planned number of patients is 4000 as reported by ClinicalTrials.gov record.
    • 22 Dec 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top